Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

Priya U. Kumthekar, MD, details the specialized program for fellows while reflecting on her own experiences, highlights her research in brain metastases, and offers advice to both fellowship directors and current fellows in oncology.

The Northwestern Medicine Canning Thoracic Institute Hispanic Program was recently launched to offer personalized care for lung and thoracic patients in their native language, making life-saving care more accessible for the Hispanic community and people who prefer to speak Spanish by removing cultural and linguistic barriers.

Scientists develop ‘QR code for cancer cells,’ like tagging swans in a pond.

Northwestern Medicine scientists report results of the first in-human clinical trial in which they used a novel, skull-implantable ultrasound device to open the blood-brain barrier and repeatedly permeate large, critical regions of the human brain to deliver chemotherapy that was injected intravenously.

A panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.

For the second time at Northwestern Medicine, surgeons have successfully performed a double-lung transplant on a patient with stage 4 lung cancer who was being considered for hospice.

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

State of Science Summit- Ovarian Cancer: Chaired by Dario Roque, MD

Institutional Perspectives in Cancer: Breast Cancer - Chaired by William J. Gradishar, MD, FASCO, FACP

William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each space.

Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.